Amicus Therapeutics Inc. (NASDAQ:FOLD) finished Wednesday with a subtraction of -$0.45 to close at $10.41, a downside of -4.14 percent. An average of 3,751,260 shares of common stock have been traded in the last five days. There was a fall of -$0.04 in the past week, and it reached a new high 15 times over the past 12 months. The last 20 days have seen an average of 2,927,410 shares traded, while the 50-day average volume stands at 2,957,776.
FOLD stock has decreased by -13.25% in the last month. The company shares reached their 1-month lowest point of $10.13 on 09/14/22. With the stock rallying to its 52-week high on 08/25/22, shares of the company touched a low of $5.91 and a high of $12.96 in 52 weeks. It has reached a new high 8 times so far this year and lost -9.87% or -$1.14 in price. In spite of this, the price is down -19.68% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
7 days have passed since Amicus Therapeutics Inc. (FOLD) last reported insider trading activity. Crowley John F, who is Executive Chairman, most recently acquired $10,468 shares at $10.66 per share on Sep 15. In this transaction, the insider spent $111,628. President & CEO, Campbell Bradley L, disposed of 5,470 shares at a price of $11.29 on Sep 01. The insider now owns more than $61,764 worth of shares. Prior to that, Chief Financial Officer Quimi Daphne went on to Sale 4,397 shares at $11.29 each on Sep 01. An amount of $49,621 was transacted.
Amicus Therapeutics Inc. (FOLD) stock’s beta is 0.90. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.38, the price-to-book (PB) ratio at 17.64.
The quick ratio of Amicus Therapeutics Inc. for the three months ended June 29 was 2.90, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.25 and a total debt to equity ratio of 2.25 for the quarter ending June 29. Its gross profit as reported stood at $271.05 million compared to revenue of $305.51 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Amicus Therapeutics Inc.’s return on assets was -32.20%.
For the three-month period that ended June 29, Amicus Therapeutics Inc. had $151.2 million in cash and short-term investments compared to $390.65 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$62.16 million in the quarter, while revenues of -$85.26 million were grew 17.58%. The analyst consensus anticipated Amicus Therapeutics Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.21, a 4.50% surprise. For the quarter, EBITDA amounted to -$58.62 million. Shareholders own equity worth $280.5 million.
From a technical analysis perspective, let’s take a brief look at Amicus Therapeutics Inc. (FOLD) price momentum. RSI 9-day as of the close on 21 September was 36.99%, suggesting the stock is Neutral, with historical volatility in this time frame at 51.93%.
As of today, FOLD’s price is $10.68 -0.38% or -$0.04 from its 5-day moving average. FOLD is currently trading -13.82% lower than its 20-day SMA and +42.02% higher than its 100-day SMA. However, the stock’s current price level is -6.97% below the SMA50 and -0.38% below the SMA200.
The stochastic %K and %D were 29.18% and 31.36%, respectively, and the average true range (ATR) was 0.57. With the 14-day stochastic at 16.91% and the average true range at 0.57, the RSI (14) stands at 40.43%. The stock has reached -0.18 on the 9-day MACD Oscillator while the 14-day reading was at -0.42.
Morgan Stanley launched coverage on Amicus Therapeutics Inc. (NASDAQ: FOLD) in its analyst report released on September 09, 2022. The firm assigned the stock an Equal-weight rating. The consensus rating for Amicus Therapeutics Inc. (FOLD) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell FOLD, while 5 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is FOLD’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $20.00, with a median target of $14.00. Taking a look at these predictions, the average price target given by analysts for Amicus Therapeutics Inc. (FOLD) stock is $14.45.